Molecular switch for controlling transformation of colorectal cancer cell genome from MSS to MSI, inhibitor and application thereof

Microsatellite instability in the genome of colorectal cancer cells through TEAD protein or YAP/TAZ-TEAD complex as molecular switches, inhibiting or inactivating, solving the problem of difficulty in transforming MSS to MSI in the prior art and improving immune targets Towards the therapeutic effect, it provides a new option for the treatment of colorectal cancer.

CN118994353APending Publication Date: 2024-11-22YUNNAN UNIV

Patent Information

Application Number
CN202410914209.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to convert the genome of colorectal cancer cells from microsatellite-stable (MSS) to microsatellite-instable (MSI), resulting in poor efficacy of immune-targeted treatments and the lack of effective molecular switches to induce this transition.

Method used

Induce microsatellite instability in the genome of colorectal cancer cells by using TEAD proteins or YAP/TAZ-TEAD complexes as molecular switches, including the use of inhibitors such as inhibition of YAP/TAZ proteins and TEAD proteins This transition is achieved by binding, inducing allosteric effects, antagonists, palmitoylation modifications, and RNA interference or gene knockout.

Benefits of technology

Successfully transformed the genome of colorectal cancer cells from a microsatellite stable state to an unstable state, increasing the mutation load and neoantigen load of tumor cells, improving the efficacy of immune targeted therapy, and providing new therapeutic options for microsatellite stable colorectal cancer .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994353A_ABST
    Figure CN118994353A_ABST
Patent Text Reader

Abstract

The invention provides a molecular switch for controlling a colorectal cancer cell genome to be converted from MSS to MSI, and belongs to the technical field of biology, and the molecular switch comprises TEAD protein or YAP / TAZ-TEAD complex protein. By inhibiting the molecular switch or inactivating the molecular switch, microsatellite instability of colorectal cancer cells can be induced, so that the curative effect of colorectal cancer immune targeted therapy is improved, and a new choice is provided for treatment of colorectal cancer. The invention further provides a molecular switch inhibitor for controlling the colorectal cancer cell genome to be converted from MSS to MSI and application of the molecular switch inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and particularly relates to a molecular switch, an inhibitor and application thereof for controlling the genome of colorectal cancer cells to change from MSS to MSI. Background Art

[0002] Colorectal cancer is one of the common malignant tumors, and its incidence rate is increasing year by year. Due to the insidious onset of colorectal cancer, nearly half of the patients are already in the middle and late stages when they are first diagnosed, and the treatment methods are limited and the effect is poor. The mismatch repair system (MMR) is very important for the stability of the genome. If the genes encoding the main proteins of the mismatch repair system, MSH6, MSH2, PMS2, and MLH1, mutate, it will lead to the occurrence of microsatellite instability (MSI). In recent years, immune targeted therapy represented by immune checkpoint inhibitors can achieve relatively good therapeutic effects for patients with advanced colorectal cancer with high microsatellite instability or mismatch repair gene deficiency (dMMR). However, in patients with advanced cancer, only about 5% of patients have mismatch repair gene deficiency, and 95% of advanced cancer patients are microsatellite stable (MSS), and immune targeted therapy for such patients is not effective. Therefore, how to transform microsatellite stable "cold tumors" into immune responsive "hot tumors" has always been a hot topic in basic medical research and drug translation research. Currently, a large number of studies are focused on changing the colorectal tumor microenvironment and increasing tumor immune infiltration to improve response to immunotherapy, but the molecular switch that controls the transformation of MSS to MSI has not yet been found. Summary of the invention

[0003] In order to induce the transformation of the genome of colorectal cancer cells from MSS to MSI, the present invention provides a molecular switch for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI. By inhibiting or inactivating the molecular switch, microsatellite instability in the genome of colorectal cancer cells can be induced, thereby improving the efficacy of colorectal cancer immune targeted therapy, and providing a new option for the treatment of colorectal cancer.

[0004] The present invention also provides an inhibitor of a molecular switch for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI and application thereof.

[0005] The present invention is achieved through the following technical solutions:

[0006] The present invention provides a molecular switch for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI, wherein the molecular switch comprises TEAD protein or YAP / TAZ-TEAD complex protein.

[0007] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MS I, wherein the inhibitor comprises at least one of the following a to e:

[0008] a. Reagents that inhibit the binding between YAP / TAZ protein and TEAD protein;

[0009] b. Reagents that induce allosteric interaction between YAP protein and TEAD protein;

[0010] c. YAP / TAZ protein antagonists;

[0011] d. Reagents for palmitoylation modification of TEAD proteins;

[0012] e. A molecular agent for RNA interference on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene, or a molecular agent for gene knockout or knockdown on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene.

[0013] Optionally, the molecular reagent for RNA interference of Yap1 gene, Wwtr1 / Taz gene and Tead gene includes at least one of 1) to 4):

[0014] 1) shRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene;

[0015] 2) siRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene;

[0016] 3) miRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene;

[0017] 4) Targeted delivery of liposome or exosome nanoparticles of any one of 1) to 3);

[0018] The molecular reagent for knocking out or knocking down any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene includes gene editing drugs designed to target any one of the gene sequences of the Yap1 gene, Wwtr1 / Taz gene and Teads gene, including but not limited to CRISPER.

[0019] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MS I for use in inducing microsatellite instability in the genome of colorectal cancer cells.

[0020] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MS I, and uses the inhibitor in inhibiting the expression of mismatch repair proteins.

[0021] Furthermore, the mismatch repair protein includes at least one of MSH6, MSH2, PMS2 and MLH1.

[0022] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MS I for use in increasing the mutation load of tumor cells or increasing the neoantigen load of tumor cells.

[0023] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MS I for use in the preparation of a drug that induces microsatellite instability in the genome of colorectal cancer cells.

[0024] Based on the same inventive concept, the present invention provides an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MS I for use in the preparation of a drug for treating colorectal cancer.

[0025] Based on the same inventive concept, the present invention provides a drug for controlling microsatellite instability in colorectal cancer cells, wherein the active ingredient of the drug includes the above-mentioned inhibitor of the molecular switch that controls the conversion of the colorectal cancer cell genome from MSS to MSI.

[0026] Based on the same inventive concept, the present invention provides a drug for treating colorectal cancer, wherein the active ingredient of the drug includes the above-mentioned inhibitor of the molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI.

[0027] Based on the same inventive concept, the present invention provides a method for controlling microsatellite instability in the genome of colorectal cancer cells, the method comprising inhibiting the expression of the above-mentioned molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI, and / or inhibiting the binding of YAP / TAZ protein with TEAD protein.

[0028] Further, the method includes at least one of the following A to E:

[0029] A. Inhibit the binding of YAP / TAZ protein and TEAD protein;

[0030] B. Induce allosteric interaction between YAP protein and TEAD protein;

[0031] C. Block the binding of YAP protein to TAZ protein through antagonists;

[0032] D. Palmitoylation modification of TEAD protein;

[0033] E. Perform RNA interference on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene, or perform gene knockout or knockdown on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene.

[0034] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0035] 1. The present invention discloses a molecular switch for controlling the conversion of the genome of colorectal cancer cells from MSS to MSI, including TEAD protein or YAP / TAZ-TEAD complex protein. By inhibiting or inactivating the molecular switch, microsatellite instability can be induced in the genome of colorectal cancer cells. Genome instability can accumulate a large number of mutations in colorectal cancer cells, promote the production of new tumor antigens, and thus improve the efficacy of colorectal cancer immune targeted therapy, providing a new option for the treatment of colorectal cancer in people with stable microsatellite in clinical practice.

[0036] 2. The present invention discloses an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI, and uses it to induce microsatellite instability in the genome of colorectal cancer cells. The present invention uses the mouse colorectal cancer cell line CT26 as the research object, and knocks out the Tead1 / 4 gene by molecular biological means, or uses an inhibitor targeting YAP / TAZ-TEAD for treatment, so as to convert the microsatellite stable state of the genome of colorectal cancer cells into a microsatellite unstable state, and induces tumor cells with microsatellite instability to show reduced expression of mismatch repair protein, increased mutation load and increased neoantigen load. This application can increase the mutation frequency of tumor cells, stimulate the production of tumor neoantigen peptides, and realize the transformation from "cold" tumor cells that cannot respond to immunotherapy to "hot" tumor cells, providing a theoretical basis for the development of drugs for microsatellite-stable digestive tract tumors and the clinical treatment strategy of microsatellite-stable tumors combined with YAP / TAZ-TEAD targeted immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0038] Figure 1 A is the PCR verification result of Tead1 / 4 double knockout cell line;

[0039] Figure 1 B is the sequencing verification result of Tead1 / 4 double knockout cell line;

[0040] Figure 2 A and 2B are the transcriptome analysis results of Tead1 / 4 double knockout cell lines;

[0041] Figure 3 A and 3B show the expression levels of mismatch repair proteins MSH6, MSH2, PMS2, and MLH1 in Tead DKO cells;

[0042] Figure 3 C and 3D show the protein expression levels of MSH6, MSH2, PMS2, and MLH1 after treatment with different inhibitors targeting YAP / TAZ-TEAD;

[0043] Figure 4 The results of quantifying mutations in Tead knockout cell lines after exon sequencing;

[0044] Figure 5 A and 5B are the sequencing results of microsatellite sequences in Tead knockout cells;

[0045] Figure 6 A and 6B are tumor neoantigens predicted by exome sequencing. DETAILED DESCRIPTION

[0046] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0047] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0048] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0049] The technical principle of the present invention is as follows:

[0050] Studies have found that the Hippo signaling pathway controls the growth and development of tissues and organs, and plays an important role in organ size control, cell proliferation, tumorigenesis, and stem cell self-renewal. The N-terminus of YAP / TAZ interacts with the C-terminal transactivation domain of TEAD to form the YAP / TAZ-TEAD complex, which constitutes the core transcriptional module of the Hippo pathway and controls the expression of downstream genes.

[0051] The inventors explored the method of inducing microsatellite instability in cells at the cellular level, using the mouse colorectal cancer cell line CT26 as the research object. In the present invention, the inventors knocked out Tead1 and Tead4 in the colorectal cancer cell line CT26, and the transcriptome data analysis found that TEAD may regulate a series of genes related to DNA damage repair at the transcriptional level, including the key genes Msh6, Msh2, Pms2, and Mlh1 of the MMR pathway. In the colorectal cancer cell line CT26 with TEAD1 / 4 knocked out, it can be observed that the protein levels of MSH6, MSH2, PMS2, and MLH1 are reduced, DNA damage accumulates, and the genomic instability phenomenon is further detected with the accumulation of DNA mismatch errors in the genome. The occurrence of MSI is therefore detected. The inventors believe that the core transcription factor TEAD of the Hippo signaling pathway is a molecular switch that regulates the state of microsatellites in the mammalian genome, and targeting TEAD in colorectal cancer cells can induce the occurrence of microsatellite instability. Based on this, the present invention proposes a molecular switch, inhibitor, and application thereof for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI.

[0052] The following will describe in detail a molecular switch, inhibitor and application thereof for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI in combination with embodiments and experimental data.

[0053] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0054] CT26 cells: ATCC (CSTR: 19375.09.3101MOUTCM37)

[0055] Example 1

[0056] Construction of Tead knockout cell line.

[0057] To verify the regulatory function of TEAD on mismatch repair in mammals, the inventors constructed a Tead knockout cell line. The online CRISPR design tool (Red Cotton, Guangzhou, China, https: / / en.rc-cr ispr.com / ) was used to design sgRNAs (Tead1-sg1: TGTAGACCAGTCTGCTCAAGAGG; Tead1-sg2: TGGCAAGCCAAGAGATTCGGAGG; Tead4-sg1: GTAGTGGAATCAGGACACGTGGG; Tead4-sg2: GCCCTGCTACACTAAATCCCAGG), targeting the second exon of the Tead1 gene and the third exon of the Tead4 gene, respectively. The YKO-RP006-Tead1 and YKO-RP006-Tead4 plasmids containing the target sgRNA sequences were co-transfected into CT26 cells using the Neon transfection system (Thermo Fisher Scientific). 24-48h after transfection, cells expressing sgRNAs were selected with puromycin (0.5μg / ml). Cells were further limitedly diluted in 96-well plates for puromycin cell selection, and monoclonal selection was performed after a few weeks. Tead1 / 4 double knockout positive clones were verified by PCR and Sanger sequencing (see Figure 1 A and 1B). The sequences of positive clones were verified by PCR (Tead1-F1: GTGACCACAGGAAGACGCTTG; Tead1-R1: CTGTGGTTCCACACAGGTTAACATC; Tead1-R2: CTTTCCCGTCCTGAGTTTGATG; Tead4-F1: GGCTTTGGTGAGATTGAGAATAG; Tead4-R1: GAGGTGGCTGTGTTGCATTC; Tead4-R2: CTTCCTTGTGCGCGTCTTCC).

[0058] Example 2

[0059] Transcriptome sequencing of Tead knockout cells.

[0060] DKO CT26 cells and unedited parental cells were collected and sent to Beijing Biomarker Biotechnology Co., Ltd. for RNA sequencing analysis to generate gene expression data sets. P < 0.05 and Flo ld change > 2 were used as the thresholds for differential expression for differential gene selection and subsequent analysis. The NCBI database GEO accession number is GSE236855. Gene set enrichment analysis (GSEA, 4.1.0) software was downloaded from (https: / / www.broad inst itute.org / gsea / ). Gene set enrichment analysis (GSEA) showed that the DNA mismatch repair gene set was significantly inhibited in Tead DKO cells (see Figure 2 A).

[0061] Most genes involved in mismatch repair were significantly downregulated in Tead DKO cells, including genes encoding major MMR proteins, Msh6, Msh2, Pms2, and Mlh1. Figure 2 B).

[0062] Example 3

[0063] MMR protein level detection.

[0064] The Tead DKO cells were collected by trypsin digestion in the cell culture flask, and the cell proteins were extracted at 4°C. The proteins were transferred to PVDF membranes and blocked with 5% milk, and then incubated overnight with specific antibodies anti-MSH2 (Cell Signa ling Technology), anti-MSH6, anti-PMS2 (BD Biosciences), and anti-MLH1 (Abcam). The secondary antibodies were incubated and blotted with horseradish peroxidase substrate (abbkine) for quantitative analysis. The results showed that compared with wild-type CT26 cells, the levels of the four MMR proteins MSH6, MSH2, PMS2, and MLH1 in Tead DKO cells were significantly reduced (see Figure 3 A and 3B).

[0065] In addition, cells were treated with YAP / TAZ-TEAD inhibitors verteporfin (corresponding to class a in inhibitors a to e, 5 μM), TED-347 (class b, 5 μM), MYF-01-37 (class b, 5 μM), YAP-TED-IN-1TFA (class a, 100 nM), K975 (class a, 10 μM) and VT103 (class d, 100 nM) for 48 hours, and cell samples were collected to extract proteins. Tead DKO cells were collected by trypsin digestion in cell culture flasks, and cell proteins were extracted at 4°C. SDS-PAGE was run on the gel, and the proteins were transferred to PVDF membranes. After blocking with 5% milk, the membranes were incubated with specific antibodies anti-MSH2 (Cell Signa l ing Technology), anti-MSH6, anti-PMS2 (BD Biosciences), and anti i-MLH1 (Abcam) was incubated overnight, and the secondary antibody was used to develop the blot using horseradish peroxidase substrate (abbkine), and the results were quantitatively analyzed. The results showed that the levels of the four MMR proteins were significantly reduced, among which verteporfin and VT103 had better effects (see Figure 3 C and 3D).

[0066] Example 4

[0067] Whole-exome sequencing.

[0068] Inhibiting DNA mismatch repair, tumor cells will accumulate replication errors in the genome as they proliferate. WT and TeadDKO cells that have been continuously passaged for more than 4 months were collected, washed twice with DPBS, snap-frozen in liquid nitrogen, and sent to SHBIO (Shanghai, China) for whole exome sequencing (WES, 150X). SureSelectXT Mouse All Exon (Agilent Technologies) was used for exon capture. The library quality and size were determined using the Agilent4200 high-sensitivity DNA assay. 2×150bp end-to-end sequencing was performed using Illumina HiSeq. Data analysis was further performed on the SHBIO data analysis platform, and Clean Data was aligned to the mouse mm9 reference genome using BWA (0.7.12). After preliminary data quality control, the Hap lotype Caller module of GATK v3.5 was used for regional alignment and base quality recalibration, including single nucleotide variants (SNVs), insertion and deletion mutations (Indels). The Hap lotype Caller module of GATK v3.5 was used to identify the mutation results. Finally, all mutations were functionally annotated by ANNOVAR. The sequencing results showed that a large number of new single nucleotide variants (SNVs) and insertion and deletion mutations (Indels) were generated in Tead KO cells using the wild-type sequencing results as the base line to filter the mutation data. The knockout of Tead led to an increase in mutation load and genomic instability (see Figure 4 , Rep1, Rep2, and Rep3 in the figure represent the results of three independent repeated sequencing).

[0069] Example 5

[0070] SSR / STR microsatellite marker validation.

[0071] WT and Tead DKO cells were collected and sent to Shanghai Paisono Company. Fluorescently labeled PCR primers were used to amplify multiple microsatellite polymorphic sites (mBat-26, mBat-37, mBat-24, and mBat-30). The amplified fragments were then separated by high-resolution gel electrophoresis (capillary electrophoresis). The length of the amplified fragments was determined by a fluorescence detection system (ABI sequencer) to achieve typing analysis of microsatellite polymorphic sites. The results showed that Tead knockout or treatment with the targeted YAP-TEAD inhibitor VT103 induced microsatellite instability in cells (see Figure 5 A and 5B).

[0072] Example 6

[0073] Tumor neoantigen analysis.

[0074] Tead KO cells underwent MSI, suggesting that potential mutations would be transcribed, and further translated peptides would form potential tumor neoantigens. Based on the mutation results of the whole exome analysis, NetMHCcons was used to evaluate the affinity of mutant peptides and MHC-I molecules to identify potential neoantigens produced by TEAD deletion mutations in tumor cells. According to the data analysis method reported in the literature, peptides with an IC50 binding affinity of less than 50nM were screened out. Such mutant peptides are considered to be strong MHC binding peptides, and peptides with an IC50 affinity of less than 500nM are considered to be potential binders. Based on the predicted results, the inventors quantified the neoantigen load produced in Tead DKO cells induced to undergo microsatellite instability (see Figure 6 A and 6B, in the figure, 8, 9, 10, and 11-mer represent 8, 9, 10, and 11 amino acids, i.e., the length of the antigen epitope, respectively).

[0075] The above results show that targeting YAP / TAZ-TEAD can induce microsatellite instability in cells, and genomic instability further accumulates a large number of mutations in tumor cells.

[0076] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0077] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0078] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A molecular switch for controlling the transformation of the genome of colorectal cancer cells from MSS to MSI, characterized in that: The molecular switch includes TEAD protein or YAP / TAZ-TEAD complex protein.

2. An inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MSI as claimed in claim 1, characterized in that The inhibitor includes at least one of the following a to e: a. Reagents that inhibit the binding between YAP / TAZ protein and TEAD protein; b. Reagents that induce allosteric interaction between YAP protein and TEAD protein; c. YAP / TAZ protein antagonists; d. Reagents for palmitoylation modification of TEAD proteins; e. A molecular agent for RNA interference on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene, or a molecular agent for gene knockout or knockdown on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene.

3. An inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MSI according to claim 2, characterized in that: The molecular reagent for RNA interference of Yap1 gene, Wwtr1 / Taz gene and Tead gene comprises at least one of 1) to 4): 1) shRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene; 2) siRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene; 3) miRNA targeting any one of the Yap1 gene, Wwtr1 / Taz gene, and Tead gene; 4) Targeted delivery of liposome or exosome nanoparticles of any one of 1) to 3); The molecular reagent for knocking out or knocking down any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene includes gene editing drugs designed to target any one of the gene sequences of the Yap1 gene, Wwtr1 / Taz gene and Teads gene, including but not limited to CRISPER.

4. Use of an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI as described in claim 2 or 3 in inducing microsatellite instability in the genome of colorectal cancer cells.

5. Use of an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI as claimed in claim 2 or 3 in inhibiting the expression of mismatch repair proteins.

6. The use according to claim 5, characterized in that: The mismatch repair protein includes at least one of MSH6, MSH2, PMS2 and MLH1.

7. Use of an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI as described in claim 2 or 3 in increasing the mutation load of tumor cells or increasing the neoantigen load of tumor cells.

8. Use of an inhibitor of a molecular switch that controls the conversion of the colorectal cancer cell genome from MSS to MSI as claimed in claim 2 or 3 in the preparation of a drug that induces microsatellite instability in the colorectal cancer cell genome.

9. Use of an inhibitor of a molecular switch that controls the conversion of the genome of colorectal cancer cells from MSS to MSI as claimed in claim 2 or 3 in the preparation of a drug for treating colorectal cancer.

10. A drug for controlling microsatellite instability in colorectal cancer cells, characterized in that: The active ingredient of the drug includes an inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MSI as described in claim 2 or 3.

11. A drug for treating colorectal cancer, characterized in that: The active ingredient of the drug includes an inhibitor of a molecular switch that controls the transformation of the genome of colorectal cancer cells from MSS to MSI as described in claim 2 or 3.

12. A method for controlling microsatellite instability in the genome of colorectal cancer cells, characterized in that: The method comprises inhibiting the expression of the molecular switch according to claim 1, and / or inhibiting the binding of YAP / TAZ protein to TEAD protein.

13. A method for controlling microsatellite instability in the genome of colorectal cancer cells according to claim 12, characterized in that: The method comprises at least one of the following A to E: A. Inhibit the binding of YAP / TAZ protein and TEAD protein; B. Induce allosteric interaction between YAP protein and TEAD protein; C. Block the binding of YAP protein to TAZ protein through antagonists; D. Palmitoylation modification of TEAD protein; E. Perform RNA interference on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene, or perform gene knockout or knockdown on any one of the Yap1 gene, Wwtr1 / Taz gene and Tead gene.

Citation Information

Patent Citations

  • Small-molecule inhibitor YAP1-Y7 for YAP1, and application thereof

    CN113461587A

  • Inhibitors of YAP / TAZ-TEAD oncoprotein, synthesis and uses thereof

    CN116490201A

  • Pharmaceutical combinations and uses thereof

    US20240197715A1

Cited By

  • Gene knockout MSH2 tumor cell vaccine as well as preparation method and application thereof

    CN120714014A

  • Application of TEAD1 palmitoylation inhibitor VT103 in preparation of PD-1 immune checkpoint antibody sensitization drug

    CN121243167A